UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ For the transition period from ___ to ___ Commission File No. 001-36297 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 77-0551645 (State or other ...

Third, we have an experienced proven commercial team with a track record of success along with an established base of customers. Recall that this team successfully launched the RHA collection under the same strategy despite the operational challenges presented by the COVID-19 pandemic. We safely conducted thousands of inperson and virtual trainings to onboard our sales team and customers. With DAXXIFYÂ's introduction to the market, we look forward to deepening our relationships with our existing practice pa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ For the transition period from ___ to ___ Commission File No. 001-36297 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 77-0551645 (State or other ...

Forward-Looking Statements | --- | --- | --- | --- | --- | --- | |--------------|-------|-------|-------|-------|-------| | | | | | | | | REVANCE | | | | | | | Investor | | | | | | | Presentation | | | | | | | NASDAQ: RVNC | | | | | | | | | | | | | | March 2023 | | | | | | This presentation also contains estimates and other statistical data made by independent parties and by us relcling to nacket size and growth and other odata doubut our inc of assumptions and limitations, and you are coulioned not to give ...

Company Participants Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2022 Earnings Conference Call February 28, 2023 4:30 AM ET Jessica Serra – Head of Investor Relations and ESG Mark Foley – Chief Executive Officer Dustin Sjuts – President Toby Schilke – Chief Financial Officer Conference Call Participants David Amsellem – Piper Sandler Annabel Samimy – Stifel Seamus Fernandez – Guggenheim Securities Stacy Ku – Cowen Balaji Prasad – Barclays Lachlan Hanbury-Brown – William Blair Terence Flynn – Morgan Stanley ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File No. 001-36297 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 77-0551645 State or other juris ...

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET Company Participants Jessica Serra - Head of Investor Relations & ESG Mark Foley - Chief Executive Officer Dustin Sjuts - President Tobin Schilke - Chief Financial Officer & Principal Accounting Officer Conference Call Participants Chris Shibutani - Goldman Sachs Ken Cacciatore - Cowen David Amsellem - Piper Sandler Stacy Lee - Stifel Justin Phillips - Morgan Stanley Rohit Bhasin - Needham & Company Operator ...

Call Start: 16:30 January 1, 0000 5:20 PM ET Revance Therapeutics, Inc. (NASDAQ:RVNC) Q2 2022 Earnings Conference Call August 9, 2022 16:30 ET Company Participants Jessica Serra - Head of Investor Relations & ESG Mark Foley - Chief Executive Officer Dustin Sjuts - President Tobin Schilke - Chief Financial Officer & Principal Accounting Officer Conference Call Participants Seamus Fernandez - Guggenheim Partners Ken Cacciatore - Cowen Annabel Samimy - Stifel David Amsellem - Piper Sandler Tim Lugo - William B ...

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Jessica Serra – Head-Investor Relations and ESG Mark Foley – Chief Executive Officer Dustin Sjuts – President Toby Schilke – Chief Financial Officer Conference Call Participants Ken Cacciatore – Cowen and Co Seamus Fernandez – Guggenheim David Amsellem – Piper Sander Annabel Samimy – Stifel Balaji Prasad – Barclays Vamil Divan – Mizuho Securities Douglas Tsao – H.C. Wainwright Rohit Bhasin ...

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2021 Earnings Conference Call February 28, 2022 4:30 PM ET Company Participants Jessica Serra - Head, IR & and ESG Mark Foley - CEO Dustin Sjuts - President Toby Schilke - CFO Conference Call Participants Ken Cacciatore - Cowen and Company Alena Seamus Fernandez - Guggenheim David Amsellem - Piper Sandler Annabel Samimy - Stifel Balaji Prasad - Barclays Tim Lugo - William Blair Douglas Tsao - H.C. Wainwright Serge Belanger - Needham & Company Disclaimer*: This tra ...